Therapeutic gene silencing is a promising approach for treatment of cancer. Despite substantial efforts, however, only few such therapeutic methods have been clinically tested. The heterogeneity in gene expression profiles among malignant tissues and the dynamic control of gene expression in individual tumors makes identifying universal and effective targets a challenge. Further development of gene silencing therapy requires new approaches to comprehend and manage gene expression in cancer cells. In this study, we proposed and evaluated experimentally a new approach to design multi-gene silencing therapy. Using a simplified model of gene expression control, we show that genes commonly regulated by the same microRNA represent optimal combinations of targets for small hairpin RNA/small interfering RNA-based gene silencing. The proposed method of target gene selection and co-silencing can be explored as an algorithm for personalized cancer gene therapy.
INTRODUCTION
Widespread alterations in gene expression are a hallmark of cancer, and these tumorigenic changes have important implications in experimental and practical oncology. For over 20 years, a substantial portion of cancer research has focused on evaluating potential targets and developing gene-silencing therapeutics. The idea of multi-target gene therapy is not new, 1 and various strategies to improve therapeutic efficacy of the combined silencing of multiple genes have been investigated. Targeting different regulatory pathways 2 and concomitant inhibition of upstream and downstream signals 3 have been explored in several studies on the basis of the concept of cascade-like or 'hierarchical' regulation of gene expression. However, the native redundancy of gene expression control mechanisms (for example, regulatory loops, pathway cross talk and divergences) reduces the efficacy of this approach and sometimes lead to unpredictable results. 4 In the present study, we explored the concept of 'collaborative' or 'democratic' regulation of gene expression. 5 In order to develop the model, we substantially simplified the complex network of cancer-related alterations and mechanistically subdivided the network into several levels on the basis of (i) genome structure, (ii) transcriptional control and (iii) post-transcriptional regulation. Genes, confirmed separately as efficient targets, were combined on the basis of probable co-regulation at one of these levels. We then simultaneously silenced such predicted combinations of genes in ovarian cancer (OC) cell lines and measured the growth inhibitory effects in order to experimentally validate our model.
OC was selected as a model for present study for several reasons. First, gene expression alterations associated with OC and their therapeutic implementations have been extensively studied by our 6, 7 and other research groups. Data available to download from various public resources provides with sufficient material for analysis and preliminary selection of potential target genes. Second, dissemination of OC is largely confined by peritoneal cavity and associated with accumulation of malignant ascites with suspended cancer cells. These specific clinical characteristics allow tumor materials to be obtained for personalized definition of optimal target genes and even experimental estimation of optimal target combination. Finally, OC restricted by peritoneal cavity presents an optimal condition for regional application of genesilencing therapeutics.
MATERIALS AND METHODS

Microarrays-based selection of target genes
Transcriptome profiling data were downloaded from the Gene Expression Omnibus database repository. Complete genome-wide expression profiles for 399 samples of serous OC and 23 samples of normal ovaries were included in analysis (Supplementary Table S1 ). First, the platform HGU133Aplus2 was mapped to the platform HGU133A, using the match tables available at the Netaffx analysis center (http://www.affymetrix.com). The downloaded raw data were MAS 5.0 normalized in the R statistical environment (http://www.R-project.org), using the Bioconductor package Affy (http://www.bioconductor.org). To eliminate the effects of different factory-default setting for average expression on the HGU133Aplus2 and HGU133A platforms, a second normalization was performed to set the average expression for each array to 1000. Then, gene expression data was imported into BRB-Arraytools 3.8.0_beta1 (National Cancer Institute/ Division of Cancer Treatment and Diagnosis (NCI/DCTD), Rockville Pike, MD, USA). Thresholding the intensity at the minimum value was performed if the spot intensity was below the minimum value of 10. If o20% of expression data had at least a 1.5 -fold change in either direction from gene's median value, and the percent of data missing or filtered out exceeded 50%, then the gene was discarded. Finally, OC was profiled versus tissue of normal ovary by significance analysis of microarrays, with false discovery rate set to 0.05. The resulting list of genes significantly overregulated in OC was analyzed one by one to select genes already validated as promising therapeutic targets (Supplementary Table S2 ).
Thirty genes were chosen for further analysis. The complete overview of the applied analytical pathway is presented in Figure 1a .
Target-genes combination
For any of 30 genes included in the analysis, the following data were collected: chromosome localization, in silico-predicted binding sites for transcription factor (TF) in the promoter region of the gene and for conserved micro RNA (miRNA) in the messenger RNA (mRNA). TRANSFAC suite was used to identify transcription factor binding sites through gene regulatory regions up to 1000 bp upstream transcription start site. Search of target sites for miRNAs through mRNA molecules was done using an online available tool (http://www.microRNA.org). All data along with coded protein function were combined in a spreadsheet table, and the genes were grouped on the basis of co-localization, transcriptional or post-transcriptional co-regulation and coded protein function.
In vitro gene silencing miRNA Simplified model of gene regulation As single gene silencing resulted in twofold suppression of OC cell growth at the best, our further effort was focused on devising optimal combinations of genes for multi-target silencing. As discussed previously, the control of gene expression might be considered as a network or a three-dimensional mesh, with multiple hubs and divergences. However, the understanding of such regulatory systems is far from complete, and attempts to model them require substantial simplification. We considered that (i) genes, which are closely located in the genome, could be coamplified and/or epigenetically co-regulated; (ii) expression of genes regulated by the same TF could be induced simultaneously;
and (iii) the stability of mRNAs modulated by the same miRNA could be affected together. We did not consider other regulatory factors, such as various types of non-coding RNAs, nuclear architectural proteins, enzymes or cofactors. Other interaction types, like TF-regulated expression of miRNA genes or miRNAmediated control of TF mRNA stability, and regulatory pathways formed by genes were ignored. Thus, in our simplified model, all genes can be equally influenced by three types of regulatory factors: chromosome localization, TFs and miRNAs. Any of these three factors can form groups of co-regulated genes and any gene can be a part of many groups. We assumed that these regulatory factors are the main targets of cancer-related expression alterations, whereas expression shifts in corresponding groups of genes are secondary events. Experimental targeting such altered regulatory hubs could establish new patterns for co-regulated gene modules, and presents an attractive therapeutic strategy to be developed in the future. As a first application of our model, we evaluated which genes are likely to be regulated by the same factor, and targeted them simultaneously.
Combination of target genes and multi-target silencing All the data for the selected 30 target genes necessary for combining them, including chromosome localization, predicted TF binding to the promoter region, miRNA binding to the associated mRNA molecules, along with coded protein function were collected (Supplementary Table S2 ). Genes were distributed into groups on the basis of colocalization and co-regulation. On the basis of the results from the single-gene silencing experiments, the two most effective target genes from each group were selected and were silenced simultaneously. In addition, the following gene combinations were included in the experiments for comparison. First, considering protein function, genes encoding TFs and signaling molecules implicated in cell proliferation were combined pairwise. Second, considering the results of the single-gene silencing experiments, four of the most effective target genes were combined into various pairs in order to determine whether simply combining experimentally validated target genes could represent a valid strategy. Dual gene targeting was performed using four shRNA constructs against any gene pair (as described in the Materials and methods), keeping the same transfection condition as for single-gene targeting experiments. As shown in Figure 1b , the optimal target gene combinations for all cell lines were based on miRNA co-regulation. The differences between the antiproliferative effects of miRNA-co-regulated dual gene targeting (Figure 1b indicated that combination of miRNA-co-regulated genes led to an increased therapeutic impact, whereas simultaneous silencing of individually effective and randomly paired target genes did not improve the growth suppressive effect. In some cases (for instance, PTK and RSF1), such combination even reduced the growth suppressive effect achieved by silencing of any of these genes separately.
Conclusions and outlook
This pilot study provides a first experimental exploration of the concept of a 'democratic' model for gene expression control and miRNA-co-regulated combination of target-genes A Malek et al of its exploitation to devise optimal multi-gene targeting strategies. The results suggest an essential role of miRNAs in gene expression control, and are in agreement with the increasing numbers of bioinformatics models of miRNA-governed regulatory network. 8, 9 So far, various sophisticated approaches have been applied to reflect the intricate nature of the gene regulatory machinery. In the present study, we used an extremely simplified model, which allowed us to address practical questions and to design appropriate experiments. However, some downsides of this approach need to be considered. First, many regulatory factors, like methylation status, non-coding RNA-based transcription control, splicing variability and their interplay, were ignored. This obviously reduces the predictive value of the model. Second, most of the input data (TF and miRNAbinding sites) were in silico-predicted and not validated experimentally. It is difficult to define the correct stringency for TF and miRNA-binding site prediction, which can lead to a variable number of genes grouped together in further analyses. Further studies are needed with an improved model and an increased number of target genes and cell lines in order to confirm our hypothesis or to develop others. A larger number of simultaneously targeted genes should also be explored. Finally, the therapeutic targeting of miRNAs would present an attractive implementation of the proposed strategy.
